Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

Paused · Phase 1 · Has a placebo group

Conditions studied: Dry Age Related Macular Degeneration

In brief

The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world

Key facts

Study ID

NCT00541333

Run by

The New York Eye & Ear Infirmary

People needed

15

Starts

2007-12-01

Last updated by the study team

2013-05-03

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Dry AMD in one or both eyes
• Age 50 or above of either gender
• Signed informed consent.

You may not qualify if…

• Known sensitivity to Mannitol or Copaxone.
• Skin disease or active infection of skin.
• Active fever or active treatment for infection.
• History of other uncontrolled systemic active disease.
• Premenopausal females not using reliable birth control.
• Sensitivity to fluorescein or iodine.
• Inability to comply with study procedures.

Where it is running

• New York Eye and Ear Infirmary — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.